Ultragenyx Pharmaceutical (RARE) Inventory Average (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Inventory Average data on file, last reported at $53.5 million in Q1 2026.

• Inventory Average for Q1 2026 came in at $53.5 million, up 17.54% year-over-year; the trailing twelve-month figure through Mar 2026 was $53.5 million (up 17.54% YoY), and the FY2025 annual result was $48.5 million, up 22.83% from the prior year.
• Inventory Average climbed to $53.5 million in Q1 2026 per RARE's latest filing, from $52.1 million in the prior quarter.
• Over five years, Inventory Average peaked at $53.5 million in Q1 2026 and troughed at $17.0 million in Q1 2022.
• A 5-year average of $35.6 million and a median of $34.9 million in 2024 frame the typical range for Inventory Average.
• The sharpest annual moves came in 2023 and 2026: Inventory Average surged 56.82% in 2023, then rose 17.54% in 2026.
• A 5-year view of Inventory Average shows it stood at $24.3 million in 2022, then jumped by 35.29% to $32.9 million in 2023, then surged by 34.31% to $44.2 million in 2024, then increased by 17.96% to $52.1 million in 2025, then grew by 2.69% to $53.5 million in 2026.
• Business Quant data shows RARE's Inventory Average at $53.5 million in Q1 2026, $52.1 million in Q4 2025, and $49.3 million in Q3 2025.